Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart) - Catalog

Name

Optimal Macronutrient Intake Trial to Prevent Heart Disease (OMNI Heart)

Accession Number

HLB00831119a

Acronym

OMNI Heart

Related studies

BSI Study IDs

OHS

Is public use dataset

False

Keywords

Has Study Datasets

True

Has Specimens

True

Specimen ID Type

Coded

Study Website

The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.

False

Study type

Clinical Trial

Collection Type

Open BioLINCC Study

Cohort type

Adult

Interventions

Behavioral: Diet therapy

Study Open Date (Data)

2011-07-06

Study Open Date (Specimens)

2011-07-06

Date materials available

2010-03-04

Last updated

None

Study period

2002 - 2008

Study Contacts
NHLBI Division

DCVS

Classification

Heart

HIV study classification

non-HIV

COVID study classification

non-COVID

Pre-Website # of Specimens Shipped

2075

# of Returned Specimens

0

Conditions

Atherosclerosis
Cardiovascular Diseases
Heart Diseases
Hypertension

Objectives

The objective of this study was to compare the effects of 3 healthy diets, each with reduced saturated fat intake, on blood pressure and serum lipids.

Background

While reduced intake of saturated fat is widely recommended for the prevention of cardiovascular disease (CVD), the type of macronutrient (carbohydrate, protein, or unsaturated fat) that should replace saturated fat was unresolved.

Participants

The trial included 164 total subjects recruited from 2 clinical centers: Johns Hopkins Medical Institutions (Baltimore, MD) and Brigham and Women’s Hospital (Boston, MA). Subjects were generally healthy adults, age ≥30 years with a systolic blood pressure (SBP) 120-159 mm Hg or diastolic blood pressure (DBP) 80-99 mm Hg. This range includes individuals with prehypertension (systolic, 120-139 mm Hg or diastolic, 80-89 mm Hg) and stage 1 hypertension (systolic, 140-159 mm Hg or diastolic, 90-99 mm Hg). Exclusion criteria included diabetes, prior or active CVD, LDL-cholesterol >220 mg/dL, fasting triglycerides >750 mg/dL, weight more than 350lb, taking medication for reduction of blood pressure lipid levels, unwillingness to stop taking vitamin and mineral supplements, and alcoholic intake of more than 14 drinks per week. The mean age of the participants was 53.6 years, 45% were women, and 55% were African American.

Design

Three healthy diets were tested: a carbohydrate-rich diet similar to the DASH diet, a protein rich diet−about half from plants, and a diet rich in unsaturated fat, mostly monosaturated fat. Subjects spent 3 periods of 6 weeks on each diet. There was 2-4 week washout periods in between the diets−subjects ate their own food during these periods. At the beginning of the study there was a run-in period of 6 days, afterwards the subjects were randomized to 1 of the 6 sequences of the 3 diets. All the food during the study was provided by the researchers. The participants came to the study site weekdays for lunch and food for the other two daily meals, snacks, and weekend meals were provided for the participants to take home. Calories were adjusted in order to maintain weight and to avoid confounding effects of weight loss in the study. Potassium and sodium were also maintained during the study.

Conclusions

A healthy diet with partial substitution of carbohydrate with either protein or monosaturated fat can further lower blood pressure, improve lipid levels, and reduce estimated cardiovascular risk.

Disease classification

Publications

Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER 3rd, Conlin PR, Erlinger TP, Rosner BA, Laranjo NM, Charleston J, McCarron P, Bishop LM; OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005 Nov 16;294(19):2455-64.


Furtado JD, Campos H, Sumner AE, Appel LJ, Carey VJ, Sacks FM. Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. Am J Clin Nutr. 2010 Oct;92(4):714-22. Epub 2010 Sep 8.

Mat types

Plasma
Serum
Urine

Network

The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.

  • Subjects

    164


    Last Modified: July 28, 2014, 1:44 p.m.
  • Age
     FrequencyPercent
    26-3031.83
    31-3595.49
    36-4095.49
    41-45137.93
    46-503420.73
    51-552817.07
    56-602917.68
    61-651710.37
    66-70169.76
    71-7521.22
    76-8042.44

    Last Modified: Nov. 7, 2024, 2:56 p.m.
  • Sex
     FrequencyPercent
    Male9155.49
    Female7344.51

    Last Modified: Nov. 7, 2024, 2:56 p.m.
  • Race
     FrequencyPercent
    African American9054.88
    Non-African American7445.12

    Last Modified: Nov. 7, 2024, 2:56 p.m.

Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. PDF Section 3.0 of the BioLINCC Handbook describes the components of the review process.

  • Material Types

    Last Modified: Nov. 30, 2015, 2:06 p.m.
  • General Freeze/Thaw Status
  • Visits (Vials)

    11/07/2024

     

    Serum

    Plasma

    Urine

    Total

    Screening Visit 3

    814

    568

    1,006

    2,388

    Intervention Period 1 Week 4

    964

    1,105

    0

    2,069

    Intervention Period 1 Week 6

    654

    542

    1,005

    2,201

    Intervention Period 2 Week 4

    969

    1,103

    0

    2,072

    Intervention Period 2 Week 6

    647

    539

    982

    2,168

    Intervention Period 3 Week 4

    921

    1,060

    0

    1,981

    Intervention Period 3 Week 6

    626

    521

    952

    2,099

     

     


    Last Modified: Nov. 7, 2024, 3:02 p.m.
  • Visits (Subjects)

    11/07/2024

     

    Serum

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    161

    6.13

    Intervention Period 1 Week 4

    162

    7.71

    Intervention Period 1 Week 6

    162

    5.39

    Intervention Period 2 Week 4

    162

    7.94

    Intervention Period 2 Week 6

    162

    5.36

    Intervention Period 3 Week 4

    158

    7.70

    Intervention Period 3 Week 6

    158

    5.20

     

     

    Plasma

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    161

    1.88

    Intervention Period 1 Week 4

    162

    6.46

    Intervention Period 1 Week 6

    159

    1.87

    Intervention Period 2 Week 4

    162

    6.38

    Intervention Period 2 Week 6

    160

    1.86

    Intervention Period 3 Week 4

    157

    6.23

    Intervention Period 3 Week 6

    157

    1.79

     

     

    Urine

    Total number of subjects

    Average volume (ml) per subject

    Screening Visit 3

    143

    5.91

    Intervention Period 1 Week 6

    154

    5.70

    Intervention Period 2 Week 6

    157

    5.80

    Intervention Period 3 Week 6

    150

    5.87


    Last Modified: Nov. 7, 2024, 3:02 p.m.